linjc16/ctgov huggingface dataset:
Ocular Findings of Polycystic Ovary Syndrome

Study Overview
=================
Brief Summary
-----------------
Purpose: This study aimed to compare the ocular surface disease test results, anterior segment parameters, and ocular response analyzer (ORA) findings of polycystic ovary syndrome (PCOS) patients with those of healthy reproductive age female controls.

Official Title
-----------------
Ocular Surface Disease Test Results, Corneal Biomechanical Properties, and Structural Parameters in Patients With Polycystic Ovary Syndrome

Conditions
-----------------
Polycystic Ovary Syndrome

Intervention / Treatment
-----------------
* Other: Observation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: premenopausal with PCOS Exclusion Criteria: patients with external ocular disease other than dry eye complaints, use of topical drops that can affect the tear film layer, contact lens use histories, those who received hormone therapy for 6 months, those who have systemic medication or systemic disease that may affect the tear film layer and reproductive physiology, previous eye surgeries, smokers and alcohol users, those having diseases (Cushing's syndrome or androgen-secreting tumors) causing similar clinical findings.

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 43 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| PCOS<br>premenopausal patients with PCOS | Other: Observation<br>* Ocular Findings Observations<br>|
| control subjects<br>non-pregnant healthy control subjects | Other: Observation<br>* Ocular Findings Observations<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of the anterior segment parameter results (Pentacam). | measurement of the central corneal thickness. | 1 year | 
| Comparison of the corneal biomechanical parameter results (ocular response analyzer). | measurement of the corneal hysteresis (CH). | 1 year |
Surveillance Study of Acute Gastroenteritis in Hospitalized Children in Rural Area in Lebanon

Study Overview
=================
Brief Summary
-----------------
Acute gastroenteritis is a common cause of hospitalization in children with significant socioeconomic burden on the health community, we will follow in this observational and analytical study the admitted cases of acute gastroenteritis to the pediatric floor at the Sheikh Ragheb Harb Hospital over a period of summer time to determine the causes, etiologies and epidemiology of Age in a community hospital.

Detailed Description
-----------------
In this survey of hospitalized cases of acute gastroenteritis, children between two months and up to ten years old are included except for known cases of chronic diarrhea, malnutrition or immunodeficiency, data collected include clinical signs and symptoms, epidemiologic information and laboratory data during the hospital stay, also hospital treatment will be reviewed to determine the therapeutic options available in our country and its convenience with the disease and clinical conditions.

Official Title
-----------------
Surveillance Study of Acute Gastroenteritis in Hospitalized Children

Conditions
-----------------
Acute Gastroenteritis, Diarrhea, Rotavirus

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: children with acute gastroenteritis admitted to the pediatric floor Exclusion Criteria: chronic diarrhea or Immunodeficiency

Ages Eligible for Study
-----------------
Minimum Age: 2 Months
Maximum Age: 10 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| gastroenteritis<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Age distribution |  | one year after completing data collection | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Gastroenteritis, Hospitalized, Children
To Demonstrate the Relative Bioavailability of Azithromycin 600 mg Tablets Under Fed Conditions

Study Overview
=================
Brief Summary
-----------------
To demonstrate the bioequivalence of Azithromycin 600 mg Tablets Under Fed Conditions.

Official Title
-----------------
Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Geneva 600 mg Azithromycin Monohydrate Tablets and Pfizer Inc. (Zithromax) 600 mg Azithromycin Dihydrate Tablets in Healthy Adult Volunteers Under Fed Conditions

Conditions
-----------------
Infection

Intervention / Treatment
-----------------
* Drug: Azithromycin Monohydrate 600 mg Tablets
* Drug: Zithromax (azithromycin dihydrate) 600 mg Tablets


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening Exclusion Criteria: Positive test results for HIV or hepatitis B or C Treatment for drug or alcohol dependence Female subjects who are pregnant or lactating

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Azithromycin Monohydrate 600mg Tablets | Drug: Azithromycin Monohydrate 600 mg Tablets<br> <br> |
| Active Comparator: 2<br>Zithromax (azithromycin dihydrate)600mg Tablets | Drug: Zithromax (azithromycin dihydrate) 600 mg Tablets<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bioequivalence according to US FDA guidelines |  | 32 days |
Monitoring of Fluoroscopy Time on the Dose Delivered to the Patient During Vertebral Cementoplasty Procedures

Study Overview
=================
Brief Summary
-----------------
The interventional radiology department of the Strasbourg University Hospital performs approximately 1,000 vertebral cementoplasties per year. This is one of the most practiced procedures in the department and therefore exposes the professionals in the room to significant annual cumulative doses of irradiation. The objective of the study is to evaluate the interest of continuous visual monitoring of the fluoroscopy time by the operator on the dose delivered to the patient during an interventional radiology procedure performed under fluoroscopic control. The chosen reference examination is a single-level vertebral cementoplasty, a standardized examination that is frequent enough to allow easy data collection

Official Title
-----------------
Interest of Continuous Monitoring of the Fluoroscopy Time on the Dose Delivered to the Patient During Vertebral Cementoplasty Gestures With a Flat Panel Detector

Conditions
-----------------
Vertebra Compression Fracture

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Adult patient (≥18 years old) Man or woman Patient cared for at the HUS in interventional service for the realization of a vertebral cementoplasty of a single level between 01/06/2020 and 30/09/2020 Subject who has not expressed his opposition, after being informed, to the reuse of his data for the purposes of this research. Exclusion criteria: Patient who expressed their opposition to the reuse of their data for research purposes Vertebroplasties of more than one level History of spinal surgery or vertebroplasty near the level concerned

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess the interest of continuous visual monitoring of the fluoroscopy time by the operator on the dose delivered to the patient during an interventional radiology procedure performed under fluoroscopic control |  | up to 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Vertebral cementoplasty, Fluoroscopy time, Fluoroscopic control, Single-level vertebral cementoplasty, Vertebra Compression Fracture
Use of a Mesh to Prevent Parastomal Hernia

Study Overview
=================
Brief Summary
-----------------
Randomized, controlled, prospective study of 54 patients receiving surgery for cancer of the lower third of the rectum with a permanent end colostomy. The aim of the study was to reduce parastomal hernia (PH) occurrence by implanting a lightweight mesh in the sublay position. Patients were followed up a) clinically and b) radiologically by means of abdominal CT. In the clinical follow-up, hernias were observed in four out of 27 patients (14.8%) in the study group and in eleven out of 27 (40.7%) in the control group (p=0.03). The implantation of the mesh reduces the appearance of PH, is well tolerated, and does not increase morbidity

Official Title
-----------------
Randomized, Controlled, Prospective Study of the Use of a Mesh to Prevent Parastomal Hernia

Conditions
-----------------
Parastomal Hernia

Intervention / Treatment
-----------------
* Device: Mesh (Ultrapro ®)
* Procedure: Conventional sigmoid end colostomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients scheduled for permanent end colostomy to treat cancer of the lower third of the rectum, Aged over 18, Charlson comorbidity index below 7 Elective surgery Radical surgery Exclusion Criteria: Loop colostomies, Emergency surgery, Body mass index above 35 kg/sq.m., Palliative surgery, Hepatic cirrhosis, Severe COPD (requiring home oxygen treatment), Corticoid treatment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Patients receiving conventional sigmoid end colostomy plus a lightweight mesh Ultrapro® | Device: Mesh (Ultrapro ®)<br>* In the mesh group, the mesh was placed in the sublay position, above the peritoneum and the posterior rectus sheath of the rectus abdominis muscles, with a minimum of 5 cm of mesh around the colostomy<br>* Other names: Ultrapro ®;Procedure: Conventional sigmoid end colostomy<br>* Patients receiving conventional sigmoid end colostomy, without mesh<br>|
| Other: 2<br>Patients receiving conventional sigmoid end colostomy, without mesh | Procedure: Conventional sigmoid end colostomy<br>* Patients receiving conventional sigmoid end colostomy, without mesh<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the reduction in the incidence of Parastomal Hernia after the mesh placement |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Parastomal hernias, Tolerance of lightweight meshes, Paracolostomy hernias, Peristomal hernias
Medtronic 670G Insulin Pump and the Impact on Glycemic Control, Quality of Life, and Compliance

Study Overview
=================
Brief Summary
-----------------
Analyze the Medtronic 670g pump on glycemic control

Detailed Description
-----------------
An Analysis of the Medtronic 670g Insulin pump use in clinical practice and the impact on glycemic control , quality of life, and compliance

Official Title
-----------------
An Analysis of Medtronic 670G Insulin Pump Use in Clinical Practice and the Impact on Glycemic Control, Quality of Life, and Compliance

Conditions
-----------------
Type 1 Diabetes Mellitus

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 18 or older Documented History of Type 1 Diabetes Mellitus 3 months continuous use of the Medtronic 670g pump system given written informed consent Exclusion Criteria: Less than 3 months use of the Medtronic 670g pump system Taking any other medication, other than the insulin used in the Medtronic 670g pump, to manage their diabetes having medical conditions or taking medications that would preclude subject involvement or affect the outcomes being measured, in the opinion of the Investigator

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glycemic control while using the Medtronic MiniMed 670g system | HbA1c, fructosamine, and glycomark will be compared between the participants last visit on previous insulin therapy and the last visit using the pump | through study completion, an average of 1 year. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy of Quality of Life and satisfaction while using the MiniMed 670g system | Diabetes Treatment Satisfaction, Diabetes-dependent Quality of Life, and Pump QOL vs Previous Therapy Questionnaires will be completed by each study participant | through study completion, an average of 1 year |
Robotic-Assisted Laparoscopic Cystectomy

Study Overview
=================
Brief Summary
-----------------
Robotic cystectomy is a relatively new procedure previously described only at university centers. These studies have all been reviews of single surgeon's experiences.

Detailed Description
-----------------
Robotic Cystectomy is a relatively new procedure previously described only at university centers. These studies have all been reviews of single surgeon's experiences. Our objective is to investigate our results from this novel procedure.

Official Title
-----------------
Robotic-assisted Laparoscopic Cystectomy: Our Center's Clinical Experience

Conditions
-----------------
Cystectomy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing robotic cystectomy at Beaumont Hospital Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Robotic cystectomy<br>Patients undergoing robotic laparoscopic cystectomy at Beaumont Hospital-RO | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Robotic cystectomy, Bladder
The Effect of Pre-rehabilitation and Rehabilitation Period on Functional Status in Inpatient Stroke Patients

Study Overview
=================
Brief Summary
-----------------
Patients who underwent inpatient rehabilitation for the last 5 years were retrospectively scanned. The pre-rehabilitation and rehabilitation periods of the patients were determined. At the beginning and end of rehabilitation, patients were evaluated with the Brunsstrom, Barthel and Stroke Impact Scale. The effect of the specified durations on these scales was investigated.

Official Title
-----------------
The Effect of Pre-rehabilitation and Rehabilitation Period on Functional Status in Inpatient Stroke Patients

Conditions
-----------------
Stroke, Rehabilitation

Intervention / Treatment
-----------------
* Other: Rehabilitation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 40-90 years old Have hemodynamic stability to participate in rehabilitation Having had an ischemic or hemorrhagic stroke Exclusion Criteria: Having a serious comorbidity that may preclude rehabilitation Malignancy Aphasia Having a serious perception problem or psychiatric illness Having a history of stroke

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Rehabilitation|Stroke Rehabilitation Program|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Brunnsstrom Stages | The Brunnstrom stages of stroke recovery, or Brunnstrom approach, outlines how spasticity and involuntary motor patterns improve. Minimum score is 1, maximum score is 6. Higher score means better outcome. | immediately after Rehabilitation | 
| Barthel Index | The Barthel scale is an ordinal scale used to measure performance in activities of daily living. Each performance item is rated on this scale with a given number of points assigned to each level or ranking. It uses ten variables describing ADL and mobility. Minimum score is 0, maximum score is 100. Higher score means better outcome. | immediately after Rehabilitation | 
| Stroke Impact Scale | The Stroke Impact Scale (SIS) is a self-report questionnaire that evaluates disability and health-related quality of life after stroke. Minimum score is 0, maximum score is 100. Higher score means better outcome. | immediately after Rehabilitation |
Specimen Collection Study Protocol

Study Overview
=================
Brief Summary
-----------------
The specimens collected will be used to evaluate matrix equivalency in an immunoassay in development for the detection of IgG or IgA or IgM antibodies to SARS - CoV2 in human serum. These reagents are for in vitro diagnostic use only.

Detailed Description
-----------------
The objective of this study is to acquire paired serum, plasma and whole blood collected on a collection card from subjects with no known history of COVID-19 infection. The specimens will be collected at Biomerica in Irvine CA for specimen collection, banking, and matrix equivalency studies for projects in development at Biomerica for detection to IgG or IgA or IgM antibodies to Sars-CoV2 antibodies. Subject will also be asked to self-collect a nasal swab for COVID-19 PCR

Official Title
-----------------
Specimen Collection Study Protocol; Internal Biomerica Normal Specimen Collection and Banking for Use in COVID-19 Serological Product Development

Conditions
-----------------
Focus in on Collecting Paired Specimens for Matrix Equivalency

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged 21 and older Able to read, speak, and understand English Must weigh a minimum of 110 pounds Willing and able to donate 20 mLs of whole blood via venipuncture. [approximately ˂ 2 tablespoons] Willing and able to donate 0.040 mLs of whole blood via fingerstick Willing and able to sign the informed consent (self or authorized representative) Willing and able to self-collect a nasal swab per the provided instruction shee Exclusion Criteria: Aged less than 21 years old Unable to provide consent. Unable to donate blood via venipuncture and fingerstick. Unable to self-collect a nasal swab

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Matrix Equivalency | This study is designed to collect specimens to support specimen matrix equivalency in an in vitro diagnostic assay for the detection of COVID-19 antibodies. Additionally, specimens collected via finger stick will be used to validate a whole blood collection card that could be used in the field by trained professionals and sent back to central reference laboratories for testing. | 1 day |
Effect of Composition and Timing of Ingestion of Fluids on the Urinary Excretion of Lithogenic Substances

Study Overview
=================
Brief Summary
-----------------
Interventional crossover study on healthy volunteers aimed at evaluating the effect of the composition and timing of ingestion of different types of water on the urinary excretion of lithogenic substances; the study will also analyze the effect of potassium citrate on urine pH and lithogenic substances

Official Title
-----------------
Effect of Composition and Timing of Ingestion of Fluids on the Urinary Excretion of Lithogenic Substances

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Other: Water


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age >18 years Exclusion Criteria: Chronic malabsorption Recurrent urinary tract infections History of kidney stones

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Phase 1<br>A=oligomineral water, B=oligomineral water | Other: Water<br>* 1 liter of water in meals; 1 liter out of meals<br>|
| Experimental: Phase 2<br>A=oligomineral water, B=bicarbonate-rich water | Other: Water<br>* 1 liter of water in meals; 1 liter out of meals<br>|
| Experimental: Phase 3<br>A=bicarbonate-rich water, B=oligomineral water | Other: Water<br>* 1 liter of water in meals; 1 liter out of meals<br>|
| Experimental: Phase 4<br>A=bicarbonate-rich water, B=bicarbonate-rich water | Other: Water<br>* 1 liter of water in meals; 1 liter out of meals<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Urine composition |  | Assessed the same day of water ingestion |